Please assess the completion status of the following clinical trial:

Trial Title: Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 40-85 year old males~* Patient is newly diagnosed with clinical Stage T1a-T2c prostate cancer based on transrectal guided extended prostate biopsy of at least 10 cores.~* Patient elects to undergo 3D mapping biopsy at our center as part of prostate cancer management.~* Patient will read, understand and sign the informed consent agreement~* Patients must have a life expectancy of at least one year.~* Gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4~* Percentage positive core rate \< 50% based on sextant or extended biopsy technique.~* Prostate Volume (PV) \>15 grams.~* Negative imaging studies ( if available) during the staging period such as Bone scan, MRI and CT scan if PSA\> 10 ng.dl before initiation of the study drug~Exclusion Criteria:~* Any 5α-reductase inhibitors medications within the past 12 months before enrollment.~* Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors.~* Anticipated blood donation within the next 90 days.~* Serum PSA levels of \>20ng/dl.~* Clinical evidence of metastatic prostate cancer.~* Two documented urinary tract infections in the past year~* CHF, MI (within 6 months) or other symptomatic CVS disease~* Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric)~* Enrollment in other studies for any disease in the past 30 days~* Significant urinary incontinence~* Diagnosis of cancer that in not considered cured, except BCC of skin~* Prior transurethral resection of the prostate with a large tissue defect.~* History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology~* Previous or concurrent radiotherapy, hormonal therapy or chemotherapy

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dutasteride (Type: EXPERIMENTAL): The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.

Based on this trial design, predict the completion outcome and termination type (if applicable).